Koselugo

AstraZeneca, Merck secure FDA nod for Koselugo to treat paediatric patients with NF1 genetic disorder
Pharmaceutical Business Review
Mon, 04/13/20 - 10:46 am
AstraZeneca
Merck
FDA
Koselugo
pediatric
neurofibromatosis